AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01065350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
Study NCT01065350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
Study NCT04978155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound performed by the surgeon after locoregional anesthesia
Description: Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
Study NCT05199623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tailored Guizhi decoction
Description: Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
Study NCT05199623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory training (OT)
Description: Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
Study NCT05199623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory training (OT)
Description: Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
Study NCT01975155 — intervention group
Intervention type: OTHER
Intervention: food questionnaire
Study NCT01975155 — intervention group
Intervention type: OTHER
Intervention: Urinary mycotoxin test
Study NCT02385994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: enLighten Laser treatment with dual-pulse width and dual-wavelength
Study NCT00084370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
Study NCT00084370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oophorectomy
Study NCT01618474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX
Description: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
Study NCT01618474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
Study NCT02571374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: symbiotic group
Description: this group received sachets of symbiotic
Study NCT02571374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: this group received placebo
Study NCT03687684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-831 Matching Placebo Tablets.
Study NCT01473498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Haemodynamic management
Description: Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients.
Study NCT01473498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haemodynamic management
Description: Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg.
Study NCT04363099 — intervention group
Intervention type: OTHER
Intervention: observational
Description: observational management of outpatients COVID 19
Study NCT02239133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVATE vaginal pessary
Study NCT01338402 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Silicone hydrogel contact lens
Study NCT01653171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
Study NCT00736489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Dry powder for inhalation, single dose
Study NCT01653171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 500 mg
Description: 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
Study NCT01653171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 1000 mg
Description: 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
Study NCT02894385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
Study NCT00736489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Dry powder for inhalation, single dose
Study NCT01024829 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT01338402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color
Study NCT00736489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for inhalation, single dose
Study NCT02174887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Gemcitabine
Description: Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:
Study NCT00114608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Focus™ Neuromuscular Stimulation System
Description: Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles.
Study NCT01737099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-O
Study NCT01737099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Study NCT01737099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02395133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
Study NCT02395133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
Study NCT03737084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT Intervention
Description: The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
Study NCT02491190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Educational Module
Description: Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
Study NCT00722501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERB-257
Study NCT00722501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00962247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Television reduction device
Description: A TV allowance helps turn off the television when the time limits have been met.
Study NCT04040257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-based approach
Description: Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
Study NCT04235790 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Eye Tracking Device
Description: Eye tracking glasses
Study NCT00627900 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: bare metal stent
Description: implantation of a bare metal stent
Study NCT00627900 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cypher-Stent (Implantation of a sirolimus-eluting stent)
Description: Implantation of a sirolimus-eluting stent
Study NCT01906671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluprine
Description: Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
Study NCT01906671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puri-Nethol
Description: Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
Study NCT01338402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Hydrogel contact lens with color
Study NCT04810000 — intervention group
Intervention type: DEVICE
Intervention: tourniquet
Description: Tourniquet release before/after wound closure
Study NCT01011530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
Study NCT02935361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02935361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT00713791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 1: 10mg oral solution
Study NCT00713791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study NCT02569710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Study NCT02569710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.
Study NCT02569710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Study NCT00713791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study NCT00713791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study NCT06496685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: A structured AAT program and usual treatment in Experimental group.
Study NCT02503267 — intervention group
Intervention type: OTHER
Intervention: none intervention
Study NCT01423396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimal care of VRF
Description: VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
Study NCT01423396 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
Study NCT02064270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Use Negative Pressure Wound Therapy
Description: Application of PICO Single-Use Negative Pressure Wound Therapy
Study NCT02064270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postsurgical dressings
Description: Use of Standard postsurgical dressings
Study NCT05484856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue derived stromal cells
Description: autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
Study NCT01553604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: augmentation mammaplasty
Description: Dressing is removed on the first postoperative day
Study NCT03732625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
Study NCT03474549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tigertriever revascularization device
Description: Mechanical Thrombectomy
Study NCT01416233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous fat grafting to the orbit
Description: subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
Study NCT01933022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eligard
Description: Subcutaneous Injection
Study NCT01407211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin A
Description: 25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month
Study NCT01553604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: augmentation mammaplasty
Description: Dressing is removed on the 6th postoperative day
Study NCT01407211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month
Study NCT02514421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
Study NCT02514421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
Study NCT02514421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
Study NCT02654990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Capsules
Description: 20 mg, 10 mg or 15 mg (for dose reductions only)
Study NCT02654990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: 1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants > 75 years. Cycle 5+: once a week for all participants.
Study NCT02654990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; > 75 years: 10 mg/dose.
Study NCT03339284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate
Description: Dexamethasone injection
Study NCT03339284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrocloride
Description: Ropivacaine injection
Study NCT01662791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
Study NCT03339284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study NCT03339284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study NCT01755143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging scan sequences of the head, neck, and chest
Study NCT01468259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
Study NCT04036435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT01828983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support groups
Study NCT01828983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education webinars
Study NCT03554395 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT03554395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03554395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT04115592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa butter
Description: Consumption of cocoa butter made with chocolate confectionery
Study NCT01755143 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pacemaker System